Excitatory amino acid antagonists for acute stroke

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Focal cerebral ischemia triggers excitatory amino acid (EAA) neurotransmitter release, primarily glutamate.
• Over-stimulation of EAA receptors contributes to irreversible ischemic brain damage.
• Drugs modulating glutamate action are investigated as neuroprotective agents, but clinical efficacy remains unproven.

Purpose of the Study:

• To systematically synthesize and evaluate data from all clinical trials on EAA modulators for stroke treatment.
• To assess the evidence of efficacy and safety of different classes of EAA modulators.

Main Methods:

• Comprehensive literature search of multiple databases (MEDLINE, EMBASE) and conference proceedings.
• Inclusion of randomized controlled trials of EAA modulators administered within 24 hours of stroke onset.
• Efficacy analysis focused on parallel group trials, assessing death or dependence at 1-12 months follow-up.

Main Results:

• No significant heterogeneity in outcomes was observed across individual drugs or drug classes.
• The overall analysis showed no significant reduction in death or dependence (OR 1.03) or mortality (OR 1.02).
• Some NMDA antagonists showed trends towards increased mortality, but this was not statistically significant for the drug class.

Conclusions:

• Current evidence indicates no significant benefit or harm from drugs modulating excitatory amino acid action in stroke.
• While large reductions in death or dependence were excluded for some agents, poor mechanistic understanding limits extrapolation.
• Further clinical trials are justified due to wide confidence intervals, but commercial development of certain NMDA antagonists is unlikely.